Latest filings (excl ownership)
10-Q
2024 Q1
Quarterly report
30 Apr 24
8-K
Axonics Reports First Quarter 2024 Financial Results
30 Apr 24
10-K/A
2023 FY
Annual report (amended)
29 Apr 24
8-K
Other Events
4 Apr 24
8-K
Axonics Stockholders Approve Merger Agreement with Boston Scientific
25 Mar 24
DEFA14A
Additional proxy soliciting materials
7 Mar 24
10-K
2023 FY
Annual report
28 Feb 24
8-K
Axonics Reports Fourth Quarter and Fiscal Year 2023 Financial Results
28 Feb 24
DEFM14A
Proxy related to merger
22 Feb 24
DEF 14A
Definitive proxy
8 Jan 24
8-K
Entry into a Material Definitive Agreement
8 Jan 24
8-K
Axonics Reports Preliminary 4Q23 and Fiscal Year 2023 Revenue
8 Jan 24
10-Q
2023 Q3
Quarterly report
30 Oct 23
8-K
Axonics Reports Third Quarter 2023 Financial Results
30 Oct 23
8-K
Departure of Directors or Certain Officers
4 Oct 23
8-K
Axonics Announces CFO Retirement and Appoints Successor
21 Aug 23
10-Q
2023 Q2
Quarterly report
31 Jul 23
8-K
Axonics Reports Second Quarter 2023 Financial Results
27 Jul 23
8-K
Submission of Matters to a Vote of Security Holders
27 Jun 23
8-K
Other Events
18 May 23
424B5
Prospectus supplement for primary offering
18 May 23
S-3ASR
Automatic shelf registration
4 May 23
10-Q
2023 Q1
Quarterly report
1 May 23
DEF 14A
Definitive proxy
1 May 23
8-K
Axonics Reports First Quarter 2023 Financial Results
1 May 23
8-K
Entry into a Material Definitive Agreement
6 Apr 23
S-8
Registration of securities for employees
7 Mar 23
10-K
2022 FY
Annual report
1 Mar 23
8-K
Axonics Reports Fourth Quarter and Fiscal Year 2022 Financial Results
1 Mar 23
8-K
Axonics Reports Preliminary Fiscal Year 2022 Revenue and Provides Fiscal Year 2023 Revenue Guidance
11 Jan 23
10-Q
2022 Q3
Quarterly report
9 Nov 22
8-K
Axonics® Reports Third Quarter 2022 Financial Results
31 Oct 22
8-K
Axonics® Announces Proposed Public Offering of Common Stock
5 Aug 22
424B5
Prospectus supplement for primary offering
4 Aug 22
424B5
Prospectus supplement for primary offering
2 Aug 22
424B5
Prospectus supplement for primary offering
2 Aug 22
10-Q
2022 Q2
Quarterly report
1 Aug 22
8-K
Axonics® Reports Second Quarter 2022 Financial Results
1 Aug 22
8-K
Amendments to Articles of Incorporation or Bylaws
1 Jun 22
DEFR14A
Revised proxy
13 May 22
Latest ownership filings
SC 13G/A
VANGUARD GROUP INC
13 Feb 24
SC 13G/A
FMR LLC
12 Feb 24
SC 13G/A
FMR LLC
9 Feb 24
4
Rinda Sama
2 Feb 24
4
Karen Noblett
2 Feb 24
4
John Woock
2 Feb 24
4
Alfred J Ford Jr
2 Feb 24
4
Kari Leigh Keese
2 Feb 24
4
RAYMOND W COHEN
2 Feb 24
SC 13G/A
BlackRock Inc.
25 Jan 24
4
Karen Noblett
10 Jan 24
4
Karen Noblett
28 Dec 23
144
Notice of proposed sale of securities
26 Dec 23
SC 13G/A
FMR LLC
11 Dec 23
3
Kari Leigh Keese
6 Oct 23
4
Danny L. Dearen
3 Oct 23
4/A
Danny L. Dearen
3 Oct 23
144
Notice of proposed sale of securities
21 Aug 23
4
Alfred J Ford Jr
17 Aug 23
144
Notice of proposed sale of securities
15 Aug 23
4
MICHAEL H CARREL
8 Aug 23
4
Alfred J Ford Jr
1 Aug 23
144
Notice of proposed sale of securities
28 Jul 23
4
Esteban Lopez
28 Jun 23
4
David M Demski
28 Jun 23
4
Jane E Kiernan
28 Jun 23
4
nancy lynn MD snyderman
28 Jun 23
4
MICHAEL H CARREL
28 Jun 23
4
Robert McNamara
28 Jun 23
4
Danny L. Dearen
31 May 23
4
Danny L. Dearen
25 Apr 23
4
Danny L. Dearen
24 Apr 23
144
Notice of proposed sale of securities
20 Apr 23
4
Danny L. Dearen
4 Apr 23
SC 13G/A
VANGUARD GROUP INC
10 Mar 23
4
Rinda Sama
23 Feb 23
5
RAYMOND W COHEN
15 Feb 23
SC 13G/A
VANGUARD GROUP INC
9 Feb 23
SC 13G/A
FMR LLC
9 Feb 23
4
Rinda Sama
2 Feb 23